Why Pharma Boards Confuse Scenario Models With Risk Measurements (And How to Fix It)
By [Your Name], Chief Editor, B2B Pulse
You’re sitting in a boardroom. The deck shows a tidy waterfall chart: base case, then three scenarios—best, worst, and most likely. The numbers look solid. The CEO leans in. “What’s our actual risk here?” The CFO points to the worst-case scenario. “That’s our risk exposure.”
Wrong.
That’s not risk. That’s a scenario. And the difference between the two is costing pharma and biotech boards millions in misallocated capital, delayed decisions, and regulatory hangovers.
Welcome to the hidden tension in pharma boardrooms: scenario models masquerading as risk measurements. It’s a common mistake—one that’s easy to make when you’re drowning in data and starved for clarity. But the fix isn’t more math. It’s cleaner communication.
Let’s break down why this confusion persists, what it costs, and how to build a board-level narrative that separates signal from noise.
The Core Confusion: Scenarios ≠ Risk
Here’s the fundamental misunderstanding that trips up even seasoned pharma executives:
-
A scenario model is a story about what could happen. It’s a “what if” narrative. Example: “What if our Phase III trial hits 80% efficacy? What if it only hits 50%?” Scenarios are useful for planning, not for quantifying risk.
-
Risk measurement is a probability-weighted assessment of uncertainty. It answers: “How likely is each outcome, and what’s the range of possible financial or operational impacts?” Risk is about likelihood and severity, not just outcome.
Most pharma boards conflate the two because scenario models feel concrete. They show a single number for each scenario. But when you mash the base case and the worst-case scenario into one frightening total—say, $500 million in potential losses—you lose the ability to see the decision behind the numbers.
You can’t evaluate trade-offs. You can’t assess whether the risk is worth the bet. You just see a scary number.
Why This Happens: The “One Number” Trap
The root cause is structural. Pharma boards are traditionally composed of scientific, financial, and operational experts. But they’re rarely trained in probabilistic thinking. Most executives grew up in a world where you present a single forecast—the base case—and then layer on a sensitivity analysis.
But sensitivities aren’t scenarios. And neither are risk measurements.
Here’s the typical dynamic:
- The CFO builds a financial model with a base case (e.g., $2B in revenue from a new drug).
- The R&D head adds a scenario for a delayed approval (e.g., revenue drops to $1.2B).
- The commercial team adds another for a competitor launching first (e.g., revenue at $800M).
- The board sees the worst-case figure and panics. They ask: “Is this risk acceptable?”
But they never ask: How likely is that scenario? Or: What other risks—like manufacturing issues, payer pushback, or regulatory shifts—are we not modeling?
The result? The board ends up making decisions based on a single, scary scenario instead of a portfolio of probabilities.
The Cost of Confusion: Real-World Fallout
This isn’t academic. I’ve seen it happen in three specific ways:
1. Over-Optimism in Asset Prioritization
When a board sees a best-case scenario that shows $3B in peak sales, they greenlight a pipeline asset that has only a 10% probability of success. The worst-case scenario (failure) is never properly weighted. The result? Capital is locked into a lottery ticket when it could fund a more predictable—but lower-revenue—program.
2. Paralysis in Late-Stage Decisions
A board reviewing a Phase III asset sees a scenario model where the worst case shows a 40% revenue drop. They delay the launch decision to “wait for more data.” But what they’re really doing is ignoring the probability that the drop is only 10% likely. Meanwhile, a competitor enters the market.
3. Misaligned Incentives with the C-Suite
The CEO says, “We’re risk-averse.” But the board evaluates performance based on meeting the base case. So the CEO over-invests in low-risk, low-reward programs to hit the number. The scenario model becomes a self-fulfilling prophecy—you create risk by avoiding it.
The Fix: Cleaner Numbers, Better Decisions
You cannot see a decision when the base case and scenario are mashed into one frightening total. The board needs cleaner numbers.
Here’s my playbook for separating scenario models from risk measurements:
1. Build a “Risk Heatmap” Next to Every Scenario
Every scenario in your deck should come with two metrics:
- Probability of occurrence (e.g., 15% chance)
- Impact range (e.g., revenue between $1.2B–$1.8B)
Do not present a single number. Present a range with a likelihood. The board can then see: “This worst case is a low-probability tail event, not our baseline risk.”
2. Use Decision Trees, Not Static Models
Scenario models are linear—they assume one path. Risk is nonlinear. A decision tree shows branching probabilities: if we invest $50M in development, there’s a 40% chance of approval, a 30% chance of delay, and a 30% chance of failure. Each branch has a financial outcome. Sum the probability-weighted results, and you get an expected value—not a scenario.
That expected value is your risk measurement. It tells the board: “Here’s the most likely financial outcome, accounting for all possible paths.”
3. Separate “Planning Scenarios” from “Risk Scenarios”
This is the biggest shift. Planning scenarios are for strategy. Risk scenarios are for governance. Don’t mix them in the same slide.
- Planning scenarios answer: “If the market grows 10%, what do we do?”
- Risk scenarios answer: “If we lose a key patent, what’s the downside probability?”
The board should see planning scenarios in the strategy section, and risk scenarios in a separate “Risk & Uncertainty” section—complete with probabilities, mitigation plans, and triggers for action.
4. Demand a “What Would Change Your Decision?” Question
Before you present any scenario, ask the board: “What would you need to see to change your decision?” That forces them to articulate their risk tolerance. For example: “If the probability of success drops below 50%, we stop funding.” Then build your risk measurement around that threshold.
Now the scenario model becomes a tool for triggering action, not for uncertainty.
Case Study: How One Mid-Size Biotech Fixed the Confusion
I worked with a mid-size biotech company that had a $500M pipeline decision. The CFO presented three scenarios: base case ($2B revenue), upside ($3B), and downside ($1B). The board was divided—some wanted to launch, others wanted to wait.
We rebuilt the analysis. Instead of scenarios, we built a Monte Carlo simulation that showed the distribution of outcomes. The base case had a 30% probability. The upside had a 10% probability. The downside had a 60% probability.
Suddenly, the board saw the truth: the “base case” was optimistic. The most likely outcome was actually the downside. They pivoted the strategy from a full launch to a phased rollout, conserving capital for a second program.
The difference? Probabilistic risk measurement, not scenario storytelling.
The Bottom Line: Clarity Is a Competitive Advantage
Pharma boards are under immense pressure. The stakes are high—billions of dollars in R&D, regulatory timelines, and life-changing therapies. But confusing scenario models with risk measurements is a self-inflicted wound.
You need to see the decision behind the numbers. That means:
- Scenarios for strategy
- Risk measurements for governance
- Clean, probability-based numbers that the board can act on
Don’t mash them together. Don’t let a single frightening total hijack the conversation. And for the love of good governance, stop asking “What’s the worst case?” and start asking “How likely is it?”
Because the best decision isn’t the one that avoids all risk. It’s the one that takes the right risk—with the right probability—for the right reward.
Now go fix your decks.
This article is adapted from insights shared by GTM leaders in the biotech and pharma ecosystems. For more on revenue team decision-making, subscribe to B2B Pulse.